Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis - 27/10/20
pages | 10 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Up to 40 % septic patients suffer from DIC, a symptom of systemic thrombosis. |
• | Embelin is a PAI-1 inhibitor and exhibited antithrombotic effects in animal models. |
• | Embelin dually ameliorated inflammation and thrombosis in a DIC mouse model. |
• | Embelin had mild influence on the hemostatic function of normal mice. |
• | Embelin can be beneficial for symptoms combining inflammation and thrombosis. |
Abstract |
Disseminated intravascular coagulation (DIC), an acute syndrome of systemic thrombus formation in microvasculatures throughout the body, can be induced by severe infections, e.g. sepsis. Anticoagulants are clinically used to alleviate the intensities of DIC. However, anticoagulants only reduce the thrombus formation but have negligible effects on the inflammatory conditions. We previously reported embelin, a natural product, as an inhibitor of plasminogen activator inhibitor-1 (PAI-1), suggesting the potent antithrombotic property. In this study, we used three thrombotic mice models to confirm the antithrombotic property of embelin. By combining the anti-inflammatory and the antithrombotic properties, we proposed embelin as a potent therapeutic agent for sepsis-induced DIC, which involves both inflammation and thrombosis. In a lipopolysaccharides-induced septic mice model, embelin not only significantly ameliorated the inflammation levels, but also effectively reduced the pulmonary hemorrhages and the micro-thrombi formations in lung. In contrast, low-molecular-weight-heparin, an anticoagulant, only moderately ameliorated the pulmonary hemorrhages and thrombotic obstructions, but had non-measurable effect on the inflammatory conditions. In addition, embelin alleviated the dysregulation of the global coagulation in septic mice, but did not affect the global coagulation in normal mice. Our current study demonstrates the antithrombotic property of embelin and the potency of the treatment or prevention of syndromes combining inflammation and thrombosis, e.g. sepsis-induced DIC.
Le texte complet de cet article est disponible en PDF.Abbreviations : DIC, TF, tPA and uPA, PAI-1 and PAI-2, XIAP, IL-1β, IL-6, TNF-α, TGF-β, PT, APTT, FIB, TT, D-GalN, LPS, LMWH, UFH, AUC, TTO, LD50
Chemical compounds studied in this article : Embelin (PubChem CID: 3218), Lipopolysaccharide (PubChem CID: 11970143), Low molecular-weight heparin (PubChem CID: 772)
Keywords : Sepsis, Disseminated intravascular coagulation, Inflammation, Fibrinolytic system, Plasminogen activation inhibitor 1, Embelin
Plan
Vol 130
Article 110528- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?